BDSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biodesix Inc (BDSX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts such as hedge fund buying and improved revenue growth, the technical indicators, financial performance, and lack of strong trading signals suggest a cautious approach. The stock's recent price trend and insider selling also raise concerns.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 45.051, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 12.457), with resistance at R1: 15.612. Overall, the technical indicators suggest a lack of strong upward momentum.
Hedge funds are heavily buying, with a 1991.20% increase in buying activity over the last quarter. Analysts have upgraded the stock to 'Outperform' due to strong revenue growth and an improved balance sheet.
Insiders are selling heavily, with a 531.80% increase in selling activity over the last month. The stock experienced a 5.13% decline during the regular market session and a further 3.16% drop post-market. No recent news or congress trading data to support positive sentiment.
In Q4 2025, revenue increased by 40.76% YoY to $28.755 million, showing strong growth. However, net income dropped by 51.76% YoY to -$3.98 million, and EPS declined by 56.25% YoY to -$0.49. Gross margin improved to 83.03%, up 5.43% YoY, indicating operational efficiency but ongoing profitability challenges.
William Blair upgraded Biodesix to 'Outperform' from 'Market Perform,' citing strong revenue guidance for 2026, which is 3% ahead of expectations, and an improved balance sheet. The company has exceeded targets for three consecutive quarters, showing momentum.
